Mentions
Extended reach
Total likes
Video views
AI synopsis
Numerous discussions highlight specific elements from the research, such as references to ctDNA serving as an early predictor of treatment response in non-small-cell lung cancer, and the collaboration highlighted by several contributors. Phrases like 'game changer' and 'critical research' reflect a tone of enthusiasm and urgency in the discussions, contributing to the overall positive sentiment regarding the article's impact on precision oncology.
The majority of discussions express strong support for the findings, underscoring the value of ctDNA in evaluating treatment effectiveness.
Strong interest is evident, with many participants actively discussing the significance and implications of the research.
While there are references to the methodologies, engagement is somewhat surface-level, focusing more on sharing information rather than in-depth analysis.
There is a broad consensus that the publication has significant implications for oncology, particularly in advancing monitoring practices.
A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immune checkpoint inhibitors
We at @PennCancer @PC3Innovation @PennPrecisMed are excited to announce a new #ctDNA publication in collaboration with @CancerResrch. Changes in #ctDNA reflect clinical benefit. Moving the needle forward in the field of #LiquidBiopsy! https://t.co/HwQrFR0hGO https://t.co/sX0D4PK7x6
Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitoring during #immunotherapy just published in @JCOPO_ASCO. Read here: https://t.co/iCBX6DfY2G #CTMoniTR #WhatFriendsDoes #ctDNAFriends #LCSM @hopkinskimmel https://t.co/R5n3qp852v
New @JCOPO_ASCO manuscript shows changes in #ctDNA reflect clinical benefit to #patients. https://t.co/DovVR3qM2m Read @CancerResrch's press release on key findings from the research. https://t.co/CtwiShAill #CTMoniTR #ctDNAFriends https://t.co/67bhURqHgZ
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors - via @JCOPO_ASCO https://t.co/kYvV9MMQ39
IT’S HERE! Our #ctMoniTR Step 1 Manuscript was just published in @JCOPO_ASCO . Key takeaway: Our unique consortium demonstrated reductions in ctDNA are strongly associated with better clinical outcomes. What about the details? A
RT @CancerResrch: New @JCOPO_ASCO manuscript shows changes in #ctDNA reflect clinical benefit to #patients. https://t.co/DovVR3qM2m Read…
ctMoniTR Step 1 started shortly thereafter. We identified a 3rd party data aggregator and statistical analysis team (@CRABResearch) and performed an analysis across 5 clinical trials of 200 patients with aNSCLC treated with PD(L)1. @JCOPO_ASCO https://t.co/9NOgLADSZg
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
RT @HillStirSci: Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t…
Our #ctDNA event on July 11 builds on a few years of work from @CancerResrch - we started with #ctMoniTR Step 1 (https://t.co/9NOgLADSZg) and will be sharing findings from Step 2 Module 1 - aNSCLC treated with TKI at the meeting! Register here: https://t.co/phHfZXpgUB
We need early endpoints for oncology trials - @cancerreserch started #ctMoniTR in 2019 with an aggregate analysis of patient level data across 5 trials. Findings showed decreases in ctDNA associate with improved outcomes in aNSCLC treated w/ PD(L)1. https://t.co/9NOgLADSZg (2/6)
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With NSCLC Treated With Immune Checkpoint Inhibitors https://t.co/3tfs8oz7Nz #lcsm
RT @ValsamoA: #9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With No…
RT @ValsamoA: #9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With No…
RT @ValsamoA: #9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With No…
RT @ValsamoA: #9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With No…
RT @ValsamoA: #9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With No…
RT @ValsamoA: #9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With No…
RT @ValsamoA: #9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With No…
#9 @CancerResrch collab Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer @JCOPO_ASCO https://t.co/tvVVgBQ3lw @JHUPath collab AI informed precision pathology https://t.co/ps8nF6A0iP @CCR_AACR
RT @CancerResrch: @CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to #patients. Click to read this critical res…
RT @CancerResrch: @CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to #patients. Click to read this critical res…
@CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to #patients. Click to read this critical research published in @JCOPO_ASCO. #ctMoniTR #ctDNAFriends https://t.co/doEaKBMOYV https://t.co/tcDwVCB3n2
RT @MeganPharmD: Outstanding presentation by @DrMiaLevy on utility of ctDNA! I jotted down copious references for my #precisiononcology rea…
RT @geoff_oxnard: @HKennecke @VanMorrisMD @jonathanloree @aparna1024 @Annals_Oncology @SyedAAhmad5 Great question! I see plasma TF & CT bur…
RT @geoff_oxnard: @HKennecke @VanMorrisMD @jonathanloree @aparna1024 @Annals_Oncology @SyedAAhmad5 Great question! I see plasma TF & CT bur…
RT @geoff_oxnard: @HKennecke @VanMorrisMD @jonathanloree @aparna1024 @Annals_Oncology @SyedAAhmad5 Great question! I see plasma TF & CT bur…
RT @geoff_oxnard: @HKennecke @VanMorrisMD @jonathanloree @aparna1024 @Annals_Oncology @SyedAAhmad5 Great question! I see plasma TF & CT bur…
@HKennecke @VanMorrisMD @jonathanloree @aparna1024 @Annals_Oncology @SyedAAhmad5 Great question! I see plasma TF & CT burden as orthogonal. Some big tumors dont shed, some small bone mets shed a lot. And TF is very dynamic on tx, responding sooner than scans. Great tool for drug development! Check out recent @CancerResrch paper: https://t.co/iooKR3mdU5
RT @MeganPharmD: Outstanding presentation by @DrMiaLevy on utility of ctDNA! I jotted down copious references for my #precisiononcology rea…
Outstanding presentation by @DrMiaLevy on utility of ctDNA! I jotted down copious references for my #precisiononcology reading list. I think Vega 2022 will be up first: https://t.co/iOGFWpbjwr https://t.co/oIxTr0tTvx
RT @CancerResrch: Thank you to our incredible #ctDNA manuscript co-authors and partners who collaborated with us to demonstrate that chang…
RT @CancerResrch: Thank you to our incredible #ctDNA manuscript co-authors and partners who collaborated with us to demonstrate that chang…
RT @CancerResrch: Thank you to our incredible #ctDNA manuscript co-authors and partners who collaborated with us to demonstrate that chang…
RT @CancerResrch: Thank you to our incredible #ctDNA manuscript co-authors and partners who collaborated with us to demonstrate that chang…
Thank you to our incredible #ctDNA manuscript co-authors and partners who collaborated with us to demonstrate that changes in #ctDNA reflect clinical benefit to patients in Step 1 of #ctMoniTR. @JCOPO_ASCO #ctDNAFriends https://t.co/UCrVSI37AP https://t.co/smN1mag72z
RT @CancerResrch: @CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to #patients. Click to read this critical res…
@CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to #patients. Click to read this critical research published in @JCOPO_ASCO. #ctMoniTR #ctDNAFriends https://t.co/ED6qwjX83S https://t.co/aytVeqwMZE
Check out a recent study that demonstrated strong associations between changes in ctDNA levels and clinical outcomes for NSCLC patients across multiple trials: https://t.co/AfW3jrJQz1. #PrecisionMedicine #PrecisionOncology #LiquidBiopsy #ctDNA.
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
RT @OncoViews: A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immun…
A recent study suggests #ctDNA may serve as an early predictor of treatment response in those with #NSCLC treated with immune checkpoint inhibitors
RT @NReguart: ctDNA as an early indicator of treatment benefit in NSCLC patients treated with ICIs @JCOPO_ASCO https://t.co/AksINdA84Z
RT @NReguart: ctDNA as an early indicator of treatment benefit in NSCLC patients treated with ICIs @JCOPO_ASCO https://t.co/AksINdA84Z
RT @NReguart: ctDNA as an early indicator of treatment benefit in NSCLC patients treated with ICIs @JCOPO_ASCO https://t.co/AksINdA84Z
RT @NReguart: ctDNA as an early indicator of treatment benefit in NSCLC patients treated with ICIs @JCOPO_ASCO https://t.co/AksINdA84Z
ctDNA as an early indicator of treatment benefit in NSCLC patients treated with ICIs @JCOPO_ASCO https://t.co/AksINdA84Z
In a pooled analysis of 200 pts w/ #NSCLC treated w ICI across 5 trials, consistent associations b/w reductions in #ctDNA & clinical benefit were found across multiple end pts supporting evidence that ctDNA may serve as an early predictor of Tx resp. https://t.co/q28xKXwRuo #lcsm https://t.co/KY8JYhGiwy
RT @JCOPO_ASCO:
New @CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to patients. Click to read this critical research published in @JCOPO_ASCO. #CTMoniTR #ctDNAFriends https://t.co/UCrVSI37AP https://t.co/HBhudJTcOv
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
RT @CancerResrch: New @JCOPO_ASCO manuscript shows changes in #ctDNA reflect clinical benefit to #patients. https://t.co/DovVR3qM2m Read…
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
RT @CancerResrch: New @JCOPO_ASCO manuscript shows changes in #ctDNA reflect clinical benefit to #patients. https://t.co/DovVR3qM2m Read…
RT @CancerResrch: New @JCOPO_ASCO manuscript shows changes in #ctDNA reflect clinical benefit to #patients. https://t.co/DovVR3qM2m Read…
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
RT @FDAOncology: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Can…
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors - via @JCOPO_ASCO https://t.co/kYvV9MMQ39
RT @CancerResrch: New @JCOPO_ASCO manuscript shows changes in #ctDNA reflect clinical benefit to #patients. https://t.co/DovVR3qM2m Read…
RT @Rndubois: Changes in #Circulating #Tumor #DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell #Lung #C…
New @JCOPO_ASCO manuscript shows changes in #ctDNA reflect clinical benefit to #patients. https://t.co/DovVR3qM2m Read @CancerResrch's press release on key findings from the research. https://t.co/CtwiShAill #CTMoniTR #ctDNAFriends https://t.co/67bhURqHgZ
Changes in #Circulating #Tumor #DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell #Lung #Cancer Treated With Immune Checkpoint Inhibitors https://t.co/RI7RrriOP9
#liquidbiopsy #monitoring https://t.co/VRmviWz6Rb
RT @CancerResrch: New @CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to patients. Click to read this critical re…
RT @FoundationATCG: In collaboration with @CancerResrch, #NewResearch published in @JCOPO_ASCO shows changes in #ctDNA reflect clinical ben…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @CancerResrch: New @CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to patients. Click to read this critical re…
RT @CharuAggarwalMD: We at @PennCancer @PC3Innovation @PennPrecisMed are excited to announce a new #ctDNA publication in collaboration with…
RT @GuardantHealth: In collaboration with Friends of Cancer Research, we're pleased to announce the publication of a new manuscript on ctDN…
In collaboration with Friends of Cancer Research, we're pleased to announce the publication of a new manuscript on ctDNA as an early indicator of treatment response. Read it in JCO Precision Oncology: https://t.co/yp2WJJMx7P @CancerResrch @JCO_ASCO #ctDNAFriends
RT @CharuAggarwalMD: We at @PennCancer @PC3Innovation @PennPrecisMed are excited to announce a new #ctDNA publication in collaboration with…
RT @d2merino: Proud to see this paper out – HUGE collaboration across industry, academia and regulators to provide foundational evidence th…
RT @CancerResrch: IT’S HERE! Our #ctMoniTR Step 1 Manuscript was just published in @JCOPO_ASCO . Key takeaway: Our unique consortium demons…
RT @CharuAggarwalMD: We at @PennCancer @PC3Innovation @PennPrecisMed are excited to announce a new #ctDNA publication in collaboration with…
We at @PennCancer @PC3Innovation @PennPrecisMed are excited to announce a new #ctDNA publication in collaboration with @CancerResrch. Changes in #ctDNA reflect clinical benefit. Moving the needle forward in the field of #LiquidBiopsy! https://t.co/HwQrFR0hGO https://t.co/sX0D4PK7x6
RT @CancerResrch: IT’S HERE! Our #ctMoniTR Step 1 Manuscript was just published in @JCOPO_ASCO . Key takeaway: Our unique consortium demons…
RT @CancerResrch: IT’S HERE! Our #ctMoniTR Step 1 Manuscript was just published in @JCOPO_ASCO . Key takeaway: Our unique consortium demons…
IT’S HERE! Our #ctMoniTR Step 1 Manuscript was just published in @JCOPO_ASCO . Key takeaway: Our unique consortium demonstrated reductions in ctDNA are strongly associated with better clinical outcomes. What about the details? A
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
RT @ValsamoA: Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitor…
Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitoring during #immunotherapy just published in @JCOPO_ASCO. Read here: https://t.co/iCBX6DfY2G #CTMoniTR #WhatFriendsDoes #ctDNAFriends #LCSM @hopkinskimmel https://t.co/R5n3qp852v
RT @CancerResrch: New @CancerResrch manuscript shows changes in #ctDNA reflect clinical benefit to patients. Click to read this critical re…
RT @PaperbirdsO: New article: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-…
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors https://t.co/FNFSl97C16
PubMed_ Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors https://t.co/NtcCzKgzPx
New article: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors https://t.co/DdiJCGsKoh #lungcancer #oncology https://t.co/5c88vldrOE